Nanomedicines in renal transplant rejection – focus on sirolimus

References

• Aagaard-TilleryKMJelinekDF1994Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycinCell Immunol1564935077517796
   PubMed Web of Science ®Google Scholar
• AlemdarAYSadiD2004Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic graftsCell Transplant132637115191164
   PubMed Web of Science ®Google Scholar
• AshokBArlethL2004In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporationJ Pharm Sci9324768715349957
   PubMed Web of Science ®Google Scholar
• BlumCB2002Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk modelAm J Transplant2551912118900
   PubMed Web of Science ®Google Scholar
• ClipstoneNACrabtreeGR1992Identification of calcineurin as a key signalling enzyme in T-lymphocyte activationNature35769571377362
   PubMed Web of Science ®Google Scholar
• DibraAKastratiA2005Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patientsN Engl J Med3536637016105990
   PubMed Web of Science ®Google Scholar
• EisenHJTuzcuEM2003Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipientsN Engl J Med3498475812944570
   PubMed Web of Science ®Google Scholar
• ForrestMLWonCY2006In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micellesJ Control Release110370716298448
   PubMed Web of Science ®Google Scholar
• FreitasRA2005What is namomedicineNanomedicine: Nanotechnology, Biology, and Medicine139
   Web of Science ®Google Scholar
• FrickerGDreweJ1996Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlationBr J Pharmacol118184178842452
   PubMed Web of Science ®Google Scholar
• GonwaTMendezR2003Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 monthsTransplantation7512132012717205
   PubMed Web of Science ®Google Scholar
• GubaMvon BreitenbuchP2002Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNat Med81283511821896
   PubMed Web of Science ®Google Scholar
• HalloranPF2004Immunosuppressive drugs for kidney transplantationN Engl J Med35127152915616206
   PubMed Web of Science ®Google Scholar
• HalloranPFMillerLW1996In vivo immunosuppressive mechanismsJ Heart Lung Transplant15959718913912
   PubMed Web of Science ®Google Scholar
• HariharanSZimmermanJJ2000A comparative study of the pharmacokinetic profiles of sirolimus oral solution and tablets in renal allograft patients [abstract]Transplantation69SupplS154no. 159
   Google Scholar
• HaywardGS2003Initiation of angiogenic Kaposi’s sarcoma lesionsCancer Cell31312559168
   PubMed Web of Science ®Google Scholar
• JohnsonRWKreisH2001Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressureTransplantation727778611571437
   PubMed Web of Science ®Google Scholar
• KahanBD2004Sirolimus: a ten-year perspectiveTransplant Proc3671515013304
   PubMed Web of Science ®Google Scholar
• KahanBDCamardoJS2001Rapamycin: clinical results and future opportunitiesTransplantation7211819311602840
   PubMed Web of Science ®Google Scholar
• KahanBDPodbielskiJ1998Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantationTransplantation66104069808489
   PubMed Web of Science ®Google Scholar
• KaplanBMeier-KriescheHU1998The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agentClin Pharmacol Ther6348539465841
   PubMed Web of Science ®Google Scholar
• KayserO2000Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophagesInt J Pharm196253610699730
   PubMed Web of Science ®Google Scholar
• KellyPNapoliKL2000Comparison of the pharmacokinetics of sirolimus (Rapamune) in renal transplant recipients following administration of the liquid or solid tablet formulations [abstract]Transplantation69SupplS154no. 158.
   Google Scholar
• KellyPANapoliK1999Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipientsBiopharm Drug Dispos202495310594869
   PubMed Web of Science ®Google Scholar
• KreisHOberbauerR2004Long–term benefits with sirolimus-based therapy after early cyclosporine withdrawalJ Am Soc Nephrol158091714978184
   PubMed Web of Science ®Google Scholar
• KuypersDRClaesK2003Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipientsTher Drug Monit254475112883227
   PubMed Web of Science ®Google Scholar
• LampenAChristiansU1995Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variabilityDrug Metab Dispos231315248689938
   PubMed Web of Science ®Google Scholar
• LownKSMayoRR1997Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporineClin Pharmacol Ther62248609333100
   PubMed Web of Science ®Google Scholar
• MacDonaldAScarolaJ2000Clinical pharmacokinetics and therapeutic drug monitoring of sirolimusClin Ther22Suppl BB10112110823378
   PubMed Web of Science ®Google Scholar
• McAlisterVCGaoZ2000Sirolimus-tacrolimus combination immunosuppressionLancet355376710665560
   PubMed Web of Science ®Google Scholar
• McAlisterVCKeshavamurthyM1999Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicityTransplant Proc31111010083495
   PubMed Web of Science ®Google Scholar
• McAlisterVCMahalatiK2002A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administrationTher Drug Monit243465012021624
   PubMed Web of Science ®Google Scholar
• McEwanPBaboolalK2005Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United KingdomClin Ther2718344616368455
   PubMed Web of Science ®Google Scholar
• McEwanPDixonS2006Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UKPharmacoeconomics24677916445304
   PubMed Web of Science ®Google Scholar
• MahalatiKKahanBD2001Clinical pharmacokinetics of sirolimusClin Pharmacokinet405738511523724
   PubMed Web of Science ®Google Scholar
• MasudaSUemotoS2000Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipientClin Pharmacol Ther689810310945321
   PubMed Web of Science ®Google Scholar
• Merisko-LiversidgeELiversidgeGG2003Nanosizing: a formulation approach for poorly-water-soluble compoundsEur J Pharm Sci181132012594003
   PubMed Web of Science ®Google Scholar
• MerrillJPMurrayJE1956Successful homortransplantation of the human kidney between identical twinsJAMA16027782
   PubMed Web of Science ®Google Scholar
• MoriceMCSerruysPW2002A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularizationN Engl J Med34617738012050336
   PubMed Web of Science ®Google Scholar
• MorrisPJ2004Transplantation--a medical miracle of the 20th centuryN Engl J Med35126788015616201
   PubMed Web of Science ®Google Scholar
• MullerRHJacobsC2001Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the futureAdv Drug Deliv Rev4731911251242
   PubMed Web of Science ®Google Scholar
• MullerRHKeckCM2004Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticlesJ Biotechnol1131517015380654
   PubMed Web of Science ®Google Scholar
• NoyesAAWhitneyWR1897The rate of solution of solid substances in their own solutionsJ Am Chem Soc199304
   Google Scholar
• PatravaleVBDateAA2004Nanosuspensions: a promising drug delivery strategyJ Pharm Pharmacol568274015233860
   PubMed Web of Science ®Google Scholar
• PDR2003Rapamune oral solution and tablets Physicians’ Desk ReferenceMontvaleMedical Economics Company
   Google Scholar
• PDR2006Neoral soft gelatin capsules (Novartis) Physicians’ Desk ReferenceMontvaleThomson PDR
   Google Scholar
• RosenHAbribatT2005The rise and rise of drug deliveryNat Rev Drug Discov4381515864267
   PubMed Web of Science ®Google Scholar
• SattlerMGuengerichFP1992Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and ratDrug Metab Dispos20753611385058
   PubMed Web of Science ®Google Scholar
• SayeghMHCarpenterCB2004Transplantation 50 years later--progress, challenges, and promisesN Engl J Med3512761615616214
   PubMed Web of Science ®Google Scholar
• ScottLJMcKeageK2003Tacrolimus: a further update of its use in the management of organ transplantationDrugs6312479712790696
   PubMed Web of Science ®Google Scholar
• SehgalSN1998Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClin Biochem31335409721431
   PubMed Web of Science ®Google Scholar
• SimamoraPAlvarezJM2001Solubilization of rapamycinInt J Pharm21325911165091
   PubMed Web of Science ®Google Scholar
• StalloneGSchenaA2005Sirolimus for Kaposi’s sarcoma in renal–transplant recipientsN Engl J Med35213172315800227
   PubMed Web of Science ®Google Scholar
• ThomasKKoelwelC2005Three generations of cyclosporine a formulations: an in vitro comparisonDrug Dev Ind Pharm313576616093201
   PubMed Web of Science ®Google Scholar
• TurgeonDKLeichtmanAB1994P450 3A activity and cyclosporine dosing in kidney and heart transplant recipientsClin Pharmacol Ther56253607924120
   PubMed Web of Science ®Google Scholar
• UndreNA2003Pharmacokinetics of tacrolimus-based combination therapiesNephrol Dial Transplant18Suppl 1i12512738758
   PubMed Web of Science ®Google Scholar
• ValenteJFAlexanderJW1998Immunobiology of renal transplantationSurg Clin North Am781269531932
   PubMed Web of Science ®Google Scholar
• VanBurenCT2000Sirolimus oral solution and tablets demonstrate equivalent safety and efficacy in real allografts [abstract]Transplantation69SupplS153no 157.
   Google Scholar
• VasquezEM2000Sirolimus: a new agent for prevention of renal allograft rejectionAm J Health Syst Pharm5743748quiz 449–51. 10711524
   PubMed Web of Science ®Google Scholar
• VathsalaAChouTC1990Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferationTransplantation49463721689520
   PubMed Web of Science ®Google Scholar
• VezinaCKudelskiA1975Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principleJ Antibiot (Tokyo)2872161102508
   PubMed Web of Science ®Google Scholar
• WeberDO1999NanomedicineHealth Forum J4232367
   Google Scholar
• WuFLTsaiMK2005Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipientsPharmacotherapy256465315899725
   PubMed Web of Science ®Google Scholar
• WuFLTsaiMK2005Effects of conversion from sirolimus oral solution to tablets in stable Taiwanese renal transplant recipientsJ Formos Med Assoc10422815660173
   PubMed Web of Science ®Google Scholar
• YatscoffRW1996Pharmacokinetics of rapamycinTransplant Proc2897038623483
   PubMed Web of Science ®Google Scholar
• YokoyamaM2005Drug targeting with nano-sized carrier systemsJ Artif Organs8778416094510
   PubMedGoogle Scholar
• ZimmermanJJKahanBD1997Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administrationJ Clin Pharmacol37405159156373
   PubMed Web of Science ®Google Scholar